Potential of four definitions of metabolic syndrome to discriminate individuals with different 10-year cardiovascular disease risk scores: a cross-sectional analysis of an Iranian cohort.
cardiac epidemiology
diabetes & endocrinology
epidemiology
public health
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
15 02 2022
15 02 2022
Historique:
entrez:
16
2
2022
pubmed:
17
2
2022
medline:
21
4
2022
Statut:
epublish
Résumé
We aimed to reveal the potential of four different metabolic syndrome (Mets) definitions to differentiate subjects according to 10-year risk of cardiovascular disease. A cross-sectional analysis of a prospective cohort. This study used baseline data from the Shiraz Heart Study, a prospective cohort study in Shiraz, Iran. Participants were screened against Mets definitions including modified WHO, National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), American Heart Association (AHA) and International Diabetes Federation (IDF). Also, Framingham risk score (FRS) and atherosclerotic cardiovascular disease (ASCVD) risk score were determined for each participant. A total number of 7225 participants of both genders entered the study. They were selected through defined family physician centres in different geographical areas. Urban residents with no migration plan were included. Those who were far from study centres or with disabilities that made them incapable to cooperate were excluded. Participants were 47.68% (N=3445) male with the mean age of 52.13±8.00 years. The number of subjects with Mets identified by WHO was the lowest (N=1676), while the percentage of subjects with high risk score was the highest, 17.1% (N=282) in FRS and 9.8% (N=162) in ASCVD risk score. There were statistically significant differences in the mean risk scores between participants with and without Mets according to AHA, WHO and NCEP ATP III definitions (p<0.001). In IDF definition, the risk scores of subjects with Mets were not statistically different compared with peers without Mets, neither based on FRS (p=0.247) nor ASCVD risk score (p=0.193). IDF was not the appropriate definition for discrimination of subjects with Mets and/or those at high risk of future cardiovascular events. AHA, WHO and NCEP ATP III definitions were effective to discriminate subjects with Mets from peers without Mets.
Identifiants
pubmed: 35168988
pii: bmjopen-2021-058333
doi: 10.1136/bmjopen-2021-058333
pmc: PMC8852747
doi:
Substances chimiques
Adenosine Triphosphate
8L70Q75FXE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e058333Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
JAMA. 2020 Jun 23;323(24):2526-2528
pubmed: 32573660
Int J Cardiol. 2008 Dec 17;131(1):90-6
pubmed: 18190978
Am J Cardiol. 2007 Feb 15;99(4):541-8
pubmed: 17293200
Diabetologia. 2006 Dec;49(12):2837-46
pubmed: 17021922
Biomed Res Int. 2020 Aug 11;2020:8179795
pubmed: 32851088
Eur Heart J. 2010 Mar;31(5):602-13
pubmed: 19942601
Clin Chim Acta. 2005 Oct;360(1-2):9-26
pubmed: 15982646
Int J Public Health. 2013 Dec;58(6):855-64
pubmed: 23999626
Int J Cardiol. 2013 Sep 20;168(1):369-74
pubmed: 23041003
J Am Coll Cardiol. 2019 Sep 10;74(10):e177-e232
pubmed: 30894318
Cardiol Res Pract. 2011 Mar 07;2011:653182
pubmed: 21403882
Circulation. 1998 May 12;97(18):1837-47
pubmed: 9603539
Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
BMJ Open. 2019 Apr 3;9(4):e026317
pubmed: 30948600
Biochem Med (Zagreb). 2012;22(3):276-82
pubmed: 23092060
Circulation. 2008 Feb 12;117(6):743-53
pubmed: 18212285
J Hypertens. 2018 Apr;36(4):824-833
pubmed: 29324585
Endocr Rev. 2008 Dec;29(7):777-822
pubmed: 18971485
Diabetes Care. 2009 Jun;32(6):1092-7
pubmed: 19279302
J Am Coll Cardiol. 2010 Sep 28;56(14):1113-32
pubmed: 20863953
Lancet. 2005 Sep 24-30;366(9491):1059-62
pubmed: 16182882
Endocr Pract. 2017 Apr;23(Suppl 2):1-87
pubmed: 28437620
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Diabetes Care. 2011 Jan;34(1):216-9
pubmed: 20889854
J Endocrinol Invest. 2016 Nov;39(11):1337-1346
pubmed: 27572249
Am J Kidney Dis. 2006 Sep;48(3):383-91
pubmed: 16931211
Int J Cardiol. 2016 Aug 15;217:92-8
pubmed: 27179214
Nutr Metab Cardiovasc Dis. 2016 Mar;26(3):223-31
pubmed: 26803591
Dis Model Mech. 2009 May-Jun;2(5-6):231-7
pubmed: 19407331
Int J Cardiol. 2018 May 15;259:216-219
pubmed: 29472026
Diabetes Res Clin Pract. 2010 Dec;90(3):319-25
pubmed: 20934770
Circulation. 2004 Jan 27;109(3):433-8
pubmed: 14744958
Iran J Public Health. 2021 Sep;50(9):1863-1871
pubmed: 34722382
J Health Popul Nutr. 2017 Nov 13;36(1):36
pubmed: 29132438
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45
pubmed: 24222016
BMJ Open. 2018 Oct 25;8(10):e022974
pubmed: 30366915
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
PLoS One. 2014 Aug 20;9(8):e105581
pubmed: 25141255
Prev Med Rep. 2017 Jul 19;7:211-215
pubmed: 28794957
Diabet Med. 1998 Jul;15(7):539-53
pubmed: 9686693
Int J Endocrinol. 2021 Mar 29;2021:8862456
pubmed: 33859688
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765
Nutr Metab Cardiovasc Dis. 2020 Mar 9;30(3):474-482
pubmed: 31791637
Metab Syndr Relat Disord. 2009 Oct;7(5):427-34
pubmed: 19754305
Diabetes Metab Syndr. 2018 Apr - Jun;12(2):195-201
pubmed: 29203060